🔴 HIMS is trading 10.1% down today after missing Q1 revenue estimates amid GLP-1 shift

HIMS is trading at $26.19 (-10.1%) in after-hours trading after the company missed Q1 2026 revenue estimates despite raising its full-year guidance.

• Revenue reached $608.1M, falling short of the $616.9M analyst consensus, with an EPS net loss of $0.40.
• Subscriber growth remained a bright spot, increasing 9% year-over-year to reach 2.6 million members.
• The sell-off reflects investor concern over the revenue shortfall as the company navigates a strategic shift toward branded GLP-1 medications.